Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 13/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 12/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487686 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20487553 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20487555 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20487413 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20487300 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL24080586 | 0.93 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20486833 | 0.93 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20486835 | 0.93 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20486749 | 0.92 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20486752 | 0.92 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110809576-B | FGFR kinase inhibitor and pharmaceutical use | 奥克兰联合服务有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-110809576-A | FGFR kinase inhibitor and pharmaceutical use | 奥克兰联合服务有限公司 | 2020-02-18 | — | — | CN | claimed |
| WO-2018160076-A1 | FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES | AUCKLAND UNISERVICES LIMITED (NZ) | 2018-09-07 | — | — | WO | claimed |
| CN-110809576-B | FGFR kinase inhibitor and pharmaceutical use | 奥克兰联合服务有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11192890-B2 | FGFR kinase inhibitors and pharmaceutical uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-12-07 | — | — | US | disclosed |
| CN-110809576-A | FGFR kinase inhibitor and pharmaceutical use | 奥克兰联合服务有限公司 | 2020-02-18 | — | — | CN | disclosed |
| WO-2018160076-A1 | FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES | AUCKLAND UNISERVICES LIMITED (NZ) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192890-B2 | FGFR kinase inhibitors and pharmaceutical uses | FGFR2, FGFR1, FGFR3 | FGFR1 2/4885FGFR2 1/4885FGFR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.